Change Agents

Beacon tracks a business’s visibility on AI assistants such as ChatGPT and Gemini, reviews, and listings, then suggests improvements.

Consumer health products by Change Agents Corp., including the KetoAir breathalyzer.

Catch-Up — the agentic video studio by Change Agents Corp.

The board of directors of Change Agents Corp.

The executive team of Change Agents Corp.

About Change Agents Corp. — a Nasdaq-listed company building agentic software products.

Contact Change Agents Corp. — inquiries, partnerships, and investor relations.

Change Agents builds breakthrough agentic software products that deliver material revenue increases for small businesses and content creators.

Change Agents Corp. builds breakthrough agentic software products designed to deliver material revenue increases for small businesses and content creators.

Avalon GloboCare rebrands as **Change Agents Corp** and transitions into an **agentic AI software company**, beginning trading tomorrow under the Nasdaq ticker **CHGA**. The shift focuses on expanding its AI-driven platforms, including **Beacon**, as part of its strategic pivot.

Jul 2026GlobeNewswireNews article

Change Agents Corp. (formerly Avalon GloboCare) transitions into a pure-play agentic artificial intelligence software company. The firm rebrands and lists on Nasdaq under the ticker **CHGA** starting July 22, 2026, while retaining existing shareholder ownership. The shift marks a strategic pivot toward AI-driven solutions.

Jul 2026Yahoo FinanceNews article

Avalon GloboCare is preparing to launch **Beacon**, an agentic generative engine optimization platform tailored for small businesses. The subscription-based SaaS tool will join its existing portfolio, including **Catch-Up**, an agentic video solution. Beacon targets automation of optimization tasks for small enterprises, aligning with Avalon’s recurring revenue strategy.

Jul 2026GlobeNewswireNews article

Avalon GloboCare Corp. receives a Nasdaq compliance notice for failing to meet listing requirements due to a delayed quarterly report. The company specializes in cell-based technology, cellular therapy, and precision diagnostics. Nasdaq cites non-compliance with Listing Rule 5250(c) as the reason for the notice, issued on May 22, 2024.

May 2024nasdaq.comNews article